COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

Capitol Annex -Room 131
700 Capital Avenue Frankfort, Kentucky 40601

Thursday, March 21, 2019
1:00 P.M. to 4:00 P.M.

AGENDA

I. Call to Order and Welcome

II. Executive Session (upon request)

III. Old Business
   a. Approval of Meeting Minutes

IV. New Business
   a. New Products to Market to be reviewed as single products:
      i. Epidiolex™ (Anticonvulsants)
      ii. Ajovy™ (Antimigraine, Other)
      iii. Emgality™ (Antimigraine, Other)
      iv. Talzenna™ (Oncology, Oral – Breast Cancer)
      v. Copiktra™ (Oncology, Oral – Hematologic Cancer)
      vi. Darulismo™ (Oncology, Oral – Hematologic Cancer)
      vii. Xospata® (Oncology, Oral – Hematologic Cancer)
      viii. Lorbrena® (Oncology, Oral – Lung Cancer)
      ix. Vizimpro® (Oncology, Oral – Lung Cancer)
   b. New Products to Market to be reviewed along with their respective classes:
      i. Arikayce® (Antibiotics, Inhaled)
      ii. Xofluza™ (Antivirals, Oral)
      iii. Yupelri™ (COPD Agents)

V. Clinical Criteria Review
   a. Ocaliva Criteria Review
   b. Hepatitis C Prescriber Restrictions

VI. Therapeutic Classes with Recommended Changes
   a. Antibiotics, Inhaled (includes new agent Arikayce®)
   b. Antivirals, Oral
      i. Antivirals: Herpes
      ii. Antivirals: Influenza (includes new agent Xofluza™)
   c. Cephalosporins and Related Antibiotics
      i. Antibiotics: Cephalosporins 1st Generation
      ii. Antibiotics: Cephalosporins 2nd Generation
      iii. Antibiotics: Cephalosporins 3rd Generation
   d. COPD Agents (includes new agent Yupelri™)
   e. Hepatitis B Agents
   f. HIV/AIDS
VII. Consent Agenda
   a. The following therapeutic classes have no changes recommended and may be
      voted on as a group under a consent agenda:

<table>
<thead>
<tr>
<th>Absorbable Sulfonamides</th>
<th>Hypoglycemics, Insulin and Related Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics, GI</td>
<td>Hypoglycemics, Meglitinides</td>
</tr>
<tr>
<td>Antibiotics, Vaginal</td>
<td>Hypoglycemics, Metformins</td>
</tr>
<tr>
<td>Antifungals, Oral</td>
<td>Hypoglycemics, SGLT2</td>
</tr>
<tr>
<td>Antihistamines, Minimally Sedating</td>
<td>Hypoglycemics, Sulfonylureas</td>
</tr>
<tr>
<td>Bronchodilators, Beta Agonist</td>
<td>Hypoglycemics, Thiazolidinediones (TZD)</td>
</tr>
<tr>
<td>Epinephrine, Self-Injected</td>
<td>Intrasatal Rhinitis Agents</td>
</tr>
<tr>
<td>Fluoroquinolones, Oral</td>
<td>Leukotriene Modifiers</td>
</tr>
<tr>
<td>Glucocorticoids, Inhaled</td>
<td>Macrolides</td>
</tr>
<tr>
<td>Hepatitis C Agents</td>
<td>Oxazolidinediones</td>
</tr>
<tr>
<td>Hypoglycemics, Alpha-Glucosidase Inhibitors</td>
<td>Penicillins</td>
</tr>
<tr>
<td>Hypoglycemics, Incretin Mimetics/Enhancers</td>
<td>Tetracyclines</td>
</tr>
</tbody>
</table>

VIII. Adjournment
   a. Schedule of Upcoming Meetings
      i. May 16, 2019
      ii. July 18, 2019
      iii. September 19, 2019
      iv. November 21, 2019
   b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the
Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan
Medicaid Administration web portal at: